ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 02.09 Mel-D Trial - Vitamin D following primary treatment of melanoma at high risk of recurrence

There is currently no high quality evidence to show that Vitamin D can improve melanoma prognosis. This is a pilot phase II study which aims to assess the feasibility, safety and toxicity of a loading oral dose of 500,000 IU of Vitamin D followed by a monthly oral dose of 50,000 IU of Vitamin D for 2 years in patients treated for cutaneous melanoma at high risk of recurrence.


Principal Investigator's details:
Dr Robyn Saw
Melanoma Institute Australia and Royal Prince Alfred hospital
Email: robyn.saw@melanoma.org.au

Study status - Ongoing Follow Up; Closed to Recruitment
ANZ Clinical Trials Registry number - ACTRN12609000351213

ANZMTG contact details:
Email: anzmtg0209@melanoma.org.au
Phone: +61 2 9911 7352


Return to Previous Page